CD86-28z CAR T cells elicit a strong antitumor response toward cHL cell lines in vivo. (A) Summary of the treatment schedule used for L-540 xenograft in vivo experiments. (B-D) BLI images (B), fLuc-BLI–based quantification of tumor burden (C), and Kaplan-Meier estimation of overall survival (D) of L-540 tumor-bearing mice treated with CD86-28z, CD30-28z, or CD19-28z CAR T cells, respectively. (B) Representative fLuc-BLI images of 5 mice per group of 1 of 2 independent experiments. (C-D) Pooled data from 2 independent experiments of total 10 mice per group are depicted. (E) Summary of the in vivo treatment schedule used for L-428–CD30^−/− cells xenografted into NSG mice. (F-H) BLI images (F), fLuc-BLI–based quantification of tumor burden (G), or Kaplan-Meier estimation of overall survival (H) of L-428–CD30^−/− tumor-bearing mice, treated with CD86-28z, CD30-28z, or CD19-28z CAR T cells, respectively. There were 5 mice per group. (I) Treatment scheme used to determine antigen-specific proliferation of CD86-28z CAR in cHL xenograft models in vivo. (J-M) Representative BLI images of tumor cell proliferation (fLuc-BLI images; J) or T-cell proliferation (teLuc-BLI images; K). Quantification of fLuc (L) or teLuc signal (M), respectively. There were 2 to 3 mice per group. Error bars indicate SEM. For all panels, statistical significance was calculated using 2-way ANOVA with Sidak multiple comparison correction. For Kaplan-Meier curves, statistical significance was calculated with a log-rank test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. ns, P > .05.